Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat

European Journal of Pharmaceutical Sciences

Volumn 25, Issue 1, 2005, Pages 91-103

  Vita, Marina ^a,b   Abdel Rehim, Mohamed ^c   Olofsson, Susanne ^c   Hassan, Zuzana ^a,b   Meurling, Lennart ^d   Sidén, Åke ^b   Sidén, Mabel ^b   Pettersson, Tommy ^d   Hassan, Moustapha ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d TDM Laboratory   (Sweden)

Author keywords

cdk inhibitors; Drug metabolism; HPLC; Mass spectrometry; NMR

Indexed keywords

CARBOXYLIC ACID; DRUG METABOLITE; HYDROXYL GROUP; PURINE DERIVATIVE; ROSCOVITINE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN TISSUE; CIRCULATION; CONTROLLED STUDY; DEALKYLATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; LUNG; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPLEEN; TANDEM MASS SPECTROMETRY; TESTIS; TISSUE DISTRIBUTION;

EID: 18044385804     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.02.001     Document Type: Article

References (22)

1. P. Cohen Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug. Discov. 1 2002 309 315
2. W. De Azevedo, R. Tadeu Gaspar, F. Canduri, J. Carlos Camera, and N. Jose Freitas da Silveira Molecular model of cyclin-dependent kinase 5 complexed with roscovitine Biochem. Biophys. Res. Commun. 297 2002 1154
3. W.F. De Azevedo, S. Leclerc, L. Meijer, L. Havlicek, M. Strnad, and S.H. Kim Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine Eur. J. Biochem. 243 1997 518 526
4. S. de la Motte, and A. Gianella-Borradori Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects Int. J. Pharmacokinet. Ther. 42 2004 232 239
5. D. Gherardi, V. D'adati, T.T. Chu, A. Barnett, A. Gianella-Borradori, I.H. Gelman, and P.J. Nelson Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202 J. Am. Soc. Nephrol. 15 2004 1212 1222
6. I.N. Hahntow, F. Schneller, M. Oelsner, K. Weick, I. Ringshausen, F. Fend, C. Peschel, and T. Decker Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells Leukemia 2004 1 9
7. B.S. Li, M.K. Sun, L. Zhang, S. Takahashi, W. Ma, L. Vinade, A.B. Kulkarni, R.O. Brady, and H.C. Pant Regulation of NMDA receptors by cyclin-dependent kinase-5 Proc. Natl. Acad. Sci. U.S.A. 98 2001 12742 12747
8. M. Ljungman, and M.T. Paulsen The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382 Mol. Pharmacol. 60 2001 785 789
9. L. Maggiorella, E. Deutsch, V. Frascogna, N. Chavaudra, L. Jeanson, F. Milliat, F. Eschwege, and J. Bourhis Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo Cancer Res. 63 2003 2513 2517
10. S.J. McClue, D. Blake, R. Clarke, A. Cowan, L. Cummings, P.M. Fischer, M. MacKenzie, J. Melville, K. Stewart, S. Wang, N. Zhelev, D. Zheleva, and D.P. Lane In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) Int. J. Cancer 102 2002 463 468
11. L. Meijer, A. Borgne, O. Mulner, J.P. Chong, J.J. Blow, N. Inagaki, M. Inagaki, J.G. Delcros, and J.P. Moulinoux Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 Eur. J. Biochem. 243 1997 527 536
12. L. Meijer, and E. Raymond Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials Acc. Chem. Res. 36 2003 417 425
13. O.P. Mgbonyebi, J. Russo, and I.H. Russo Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells Cancer Res. 59 1999 1903 1910
14. M. N'Cho, and Z. Brahmi Evidence that Fas-induced apoptosis leads to S phase arrest Human Immunol. 62 2001 310 319
15. W.M. Pardridge CNS drug design based on principles of blood-brain barrier transport J. Neurochem. 70 1998 1781 1792
16. J.W. Pippin, Q. Qu, L. Meijer, and S.J. Shankland Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist J. Clin. Invest. 100 1997 2512 2520
17. L.M. Schang, A. Rosenberg, and P.A. Schaffer Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins J. Virol. 74 2000 2107 2120
18. M. Vita, L. Meurling, T. Pettersson, M. Cruz-Siden, A. Siden, and M. Hassan Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat J. Pharm. Biomed. Anal. 34 2004 425 431
19. L. Vitali, J.S. Yakisich, M.F. Vita, A. Fernandez, L. Settembrini, A. Siden, M. Cruz, H. Carminatti, O. Casas, and V. Idoyaga Vargas Roscovitine inhibits ongoing DNA synthesis in human cervical cancer Cancer Lett. 180 2002 7 12
20. J.S. Yakisich, J. Boethius, I.O. Lindblom, L. Wallstedt, V.I. Vargas, A. Siden, and M. Cruz Inhibition of DNA synthesis in human gliomas by roscovitine Neuroreport 10 1999 2563 2567
21. J.S. Yakisich, A. Siden, V. Idoyaga Vargas, P. Eneroth, and M. Cruz Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine Biochem. Biophys. Res. Commun. 243 1998 674 677
22. Z. Yan, P. Chi, J.A. Bibb, T.A. Ryan, and P. Greengard Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons J. Physiol. 540 2002 761 770